167 related articles for article (PubMed ID: 31450280)
1. Onset of frontal fibrosing alopecia during inhibition of Th1/17 Pathways with ustekinumab.
King AD; Lam L; Goh C
Dermatol Online J; 2019 Jul; 25(7):. PubMed ID: 31450280
[TBL] [Abstract][Full Text] [Related]
2. Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis.
Ichihara A; Jinnin M; Ihn H
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):208-210. PubMed ID: 28422002
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab does not increase tuberculosis risk: Results from a national database in South Korea.
Cho SI; Kang S; Kim YE; Lee JY; Jo SJ
J Am Acad Dermatol; 2020 May; 82(5):1243-1245. PubMed ID: 31866266
[No Abstract] [Full Text] [Related]
4. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
5. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
Ergen EN; Yusuf N
Exp Dermatol; 2018 Jul; 27(7):737-747. PubMed ID: 29704872
[TBL] [Abstract][Full Text] [Related]
7. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
8. A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal.
Lovero R; Losurdo G; Mastromauro M; Castellaneta NM; Mongelli A; Gentile A; Di Leo A; Principi M
Curr Drug Saf; 2018; 13(3):221-223. PubMed ID: 30027852
[TBL] [Abstract][Full Text] [Related]
9. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.
Wang DM; Fernandez AP; Calabrese CM; Calabrese LH
Clin Exp Dermatol; 2019 Jan; 44(1):113-115. PubMed ID: 29797733
[No Abstract] [Full Text] [Related]
10. Ustekinumab: moving the target from psoriasis to Crohn's disease.
Settesoldi A; Coppola M; Rogai F; Annese V
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):5-13. PubMed ID: 24410468
[TBL] [Abstract][Full Text] [Related]
11. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
de Souza A; Ali-Shaw T; Reddy SM; Fiorentino D; Strober BE
Br J Dermatol; 2013 Jan; 168(1):210-2. PubMed ID: 23278559
[TBL] [Abstract][Full Text] [Related]
13. Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis.
Stöllberger C; Finsterer J
J Dermatol; 2017 Jun; 44(6):703-705. PubMed ID: 28150333
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
[TBL] [Abstract][Full Text] [Related]
16. Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.
Jones BB; Millsop JW; Walsh JA; Krueger GG; Callis Duffin K
Br J Dermatol; 2015 Jul; 173(1):272-4. PubMed ID: 25557081
[No Abstract] [Full Text] [Related]
17. Inflammatory features of frontal fibrosing alopecia.
Ma SA; Imadojemu S; Beer K; Seykora JT
J Cutan Pathol; 2017 Aug; 44(8):672-676. PubMed ID: 28429464
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
19. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
